AC Immune SA’s stock ACIU soared 13% premarket Tuesday, after the Swiss-based biotech said it has received U.S. Food and Drug Administration fast-track designation for an Alzheimer’s disease treatment. The treatment, called ACI-24.060, is an anti-amyloid beta active immunotherapy -candidate. The fast-track designation aims to accelerate the approval of treatments for serious illnesses with unmet medical needs.
Food and Drug Administration fast-track designation for an Alzheimer’s disease treatment. The treatment, called ACI-24.060, is an anti-amyloid beta active immunotherapy -candidate. The fast-track designation aims to accelerate the approval of treatments for serious illnesses with unmet medical needs. The move comes after the FDA cleared the company’s investigational New Drug application, which will allow it to expand to the U.S.